Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,556,000 | 2,203,000 | 2,161,000 | 1,697,000 | 3,300,000 |
| Receivables | 3,709,000 | 3,810,000 | 3,564,000 | 3,384,000 | 3,059,000 |
| Inventories | 3,179,000 | 3,323,000 | 3,497,000 | 3,247,000 | 3,007,000 |
| Other current assets | 2,380,000 | 2,285,000 | 2,314,000 | 2,182,000 | 2,180,000 |
| TOTAL | $13,946,000 | $12,736,000 | $12,620,000 | $11,528,000 | $12,552,000 |
| Non-Current Assets | |||||
| PPE Net | 4,080,000 | 4,820,000 | 4,810,000 | 4,631,000 | 4,581,000 |
| Intangibles | 19,781,000 | 19,881,000 | 20,091,000 | 19,666,000 | 19,565,000 |
| Other Non-Current Assets | 2,941,000 | 2,420,000 | 2,609,000 | 2,589,000 | 2,628,000 |
| TOTAL | $26,802,000 | $27,121,000 | $27,510,000 | $26,886,000 | $26,774,000 |
| Total Assets | $40,748,000 | $39,856,000 | $40,131,000 | $38,415,000 | $39,326,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,820,000 | 24,000 | 464,000 | 421,000 | 1,781,000 |
| Accounts payable and accrued liabilities | 2,531,000 | 2,355,000 | 2,498,000 | 2,290,000 | 2,203,000 |
| Accrued Expenses | 3,426,000 | 3,550,000 | 3,576,000 | 3,426,000 | 3,416,000 |
| Other current liabilities | 5,325,000 | 5,237,000 | 4,990,000 | 4,660,000 | 4,698,000 |
| TOTAL | $13,456,000 | $11,491,000 | $11,861,000 | $11,157,000 | $12,796,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 14,986,000 | 16,766,000 | 16,763,000 | 16,230,000 | 16,002,000 |
| Other Non-Current Liabilities | 4,096,000 | 3,946,000 | 4,234,000 | 4,293,000 | 4,722,000 |
| TOTAL | $19,378,000 | $21,112,000 | $21,437,000 | $20,990,000 | $21,149,000 |
| Total Liabilities | $32,834,000 | $32,602,000 | $33,297,000 | $32,146,000 | $33,946,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 1,147,283 | 1,147,151 | 1,146,960 | 1,133,839 |
| Common Shares | 58,000 | 58,000 | 58,000 | 58,000 | 58,000 |
| Retained earnings | -13,762,000 | -14,243,000 | -14,676,000 | -14,958,000 | -15,173,000 |
| Other shareholders' equity | -2,387,000 | -2,471,000 | -2,423,000 | -2,668,000 | -3,141,000 |
| TOTAL | $7,914,000 | $7,254,000 | $6,834,000 | $6,269,000 | $5,380,000 |
| Total Liabilities And Equity | $40,748,000 | $39,856,000 | $40,131,000 | $38,415,000 | $39,326,000 |